Having successfully developed a number of drugs through to regulatory approval and commercial sales, Pharmaxis (ASX: PXS) is set to realise a $2 million windfall with the sale of their Australian distribution rights, a move that will focus the Company’s efforts towards their advancing cancer treatment clinical trials. The deal will send the distribution rights
Read More
Promising early study results released today by clinical stage drug development company Pharmaxis (ASX: PXS), should be a reason for investors to stir. Pharmaxis’ latest clinical trial (MF-101) focuses on bone marrow cancer myelofibrosis and potential treatment with their hero drug, PXS-5505. Having already proven the drug’s tolerability and efficacy in terms of absorption, distribution,
Read More
The inventors of “spray-on skin”, Avita Medical (ASX: AVH) have today released their financial results for the fiscal fourth quarter with the Company reporting strong revenue. The Company was founded to develop and commercialise the RECELL “spray-on skin” product, invented in Perth by Professor Fiona Wood. Professor Wood is a world renowned surgeon and researcher
Read More
Leading fund manager Karst Peak Capital has secured a significant interest in a little-known Aussie pharmaceuticals research company, following the significant success they experienced with a large holding of Avita Medical. Originally based in Hong Kong but now also with an office in Sydney, Karst’s investment focus includes the healthcare, biotech and pharmaceuticals industry which
Read More
Streamlining operations to focus on the most profitable side of their pharmaceuticals manufacturing business, Pharmaxis (ASX: PXS) has shored up its cash position via the sale of distribution rights in Russia for their cystic fibrosis treatment which is gathering international momentum. The deal will send exclusive distribution rights in Russia to specialty company GEN İlaç
Read More
In biotech circles, tackling a rare and difficult disease with few patients does not necessarily equate to targeting an unprofitable one. In the case of fibrotic diseases specialist Pharmaxis (ASX: PXS), its proposed treatment for the rare blood cancer myelofibrosis presents a potential billion dollar-plus market, even though only about 15 in every 1 million
Read More